Webinar: Scaling-up Organ-on-chip Assays for drug discovery with AIM Biotech 3D Tissue Culture Systems and the Opentrons OT-2
In case you missed it, check out our recent webinar with our friends at Opentrons. AIM Biotech’s Sei Hein Lim talks about how to scale-up drug discovery research using AIM’s organiX and idenTx 3D tissue culture platforms in conjunction with the Opentrons OT-2 lab...
Ex vivo culture of human biopsies with idenTx: leveraging the STING pathway to complement NK-cell therapy
In a recent publication in Cancer Immunology Research, a team led by scientists at Dana-Farber Cancer Institute and Brigham and Women’s Hospital used AIM Biotech’s idenTx drug discovery platform to demonstrate the therapeutic potential of STING (stimulator of...
AIM Biotech partners with Nikon to provide organ-on-a-chip imaging and analysis contract services for drug discovery
Nikon Corporation announced on Wednesday that AIM Biotech is one of the select organ-on-a-chip (OOAC) providers to support Nikon’s expanding global contract research services for drug discovery. This partnership is a result of collaborative efforts between Nikon and...
How AIM Biotech is automating organ-on-a-chip drug discovery
AIM Biotech is using Opentron’s lab robot to implement automated drug discovery on in vitro platforms that provide more predictive data and higher throughput When the scientists at AIM Biotech developed our idenTx organ-on-a-chip (OOAC) platform for human...